RxDoctor Payments Data

John Wirick, MD

Psychiatry · Cincinnati, OHNPI 1922260454

Payments from drug & device makers

$2,170in general payments, 2019–2025

Across 140 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$489
  • Otsuka America Pharmaceutical, Inc.$355
  • Johnson & Johnson$223
  • Sunovion Pharmaceuticals Inc.$220
  • Neurocrine Biosciences, Inc.$195
  • Lundbeck LLC$158
  • plus $531 from 9 others

What the payments were for

  • Food & beverage$2,12398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$13,049
Medicare patients
50
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate196$643,008
Abilify MaintenaAripiprazole81$238,235
Invega TrinzaPaliperidone Palmitate16$157,868
IngrezzaValbenazine Tosylate14$107,310
VraylarCariprazine Hcl102$77,446
RexultiBrexpiprazole19$29,398
ClozarilClozapine11$26,235
Atomoxetine Hcl157$18,684
Risperdal ConstaRisperidone Microspheres15$18,585
CaplytaLumateperone Tosylate12$18,500
Lurasidone Hcl25$18,442
Clozapine199$15,215
Aripiprazole129$13,185
Quetiapine Fumarate ErQuetiapine Fumarate60$11,522
Haloperidol Decanoate137$9,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$223$819,460227 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$355$267,633100 claims
Neurocrine Biosciences, Inc.Ingrezza$195$107,31014 claims
AbbVieVraylar$489$77,446102 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$68$18,50012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$6,61713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →